Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactolevure
- Development stage
- Unknown
- Lead developer
- Unipharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactolevure is a multi-strain probiotic supplement developed by Uni-Pharma, designed to restore and maintain the balance of the intestinal microflora. It contains a synergistic blend of the probiotic yeast *Saccharomyces boulardii* and three bacterial strains: *Lactobacillus acidophilus*, *Lactobacillus plantarum*, and *Bifidobacterium lactis*. The mechanism of action involves the competitive inhibition of pathogenic microorganisms, the production of antimicrobial substances (such as lactic acid and bacteriocins), and the enhancement of the intestinal epithelial barrier. Additionally, it modulates the gut-associated lymphoid tissue (GALT) to support immune function. Lactolevure is primarily indicated for the prevention and treatment of antibiotic-associated diarrhea, the management of symptoms related to irritable bowel syndrome (IBS), and the restoration of gut health following acute gastroenteritis or dietary changes.
- Brand names
- Lactolevure
- Other names
- Caps Lactolevure
02
Targets
TLR2 (Toll-like Receptor 2)IL-6 (Interleukin 6)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on Lactolevure.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactolevure.